Can a new pill help hearts thickened by hypertrophic cardiomyopathy?
NCT ID NCT06816251
First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time
Summary
This trial tests an experimental drug called HRS-1893 in people with non-obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and makes it harder for the heart to pump blood. The study will see if the drug is safe and whether it can improve exercise capacity and reduce signs of heart strain. About 84 adults aged 18 to 85 will be randomly assigned to receive either HRS-1893 or a placebo, and neither they nor their doctors will know which they are getting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HRS-1893 tablet
- What this could lead to
- If successful, HRS-1893 could offer a new treatment to improve exercise capacity and heart function in people with non-obstructive hypertrophic cardiomyopathy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. The drug could also cause side effects, including a potential drop in heart pumping function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
84 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18\~85 years old (including boundary value), male or female. 2. Body mass index \< 35 kg/m2. 3. Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing. 4. Female subjects of childbearing potential must have a serum pregnancy test prior to the first dose with a negative result and must be non-lactating during the study. 5. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time of signing the informed consent form until 3 months after the last dose of the trial drug, and comply with the relevant contraceptive requirements. Exclusion Criteria: 1. Known or suspected infiltration, hereditary, or storage disorder that can cause myocardial hypertrophy. 2. Paroxysmal atrial flutter or atrial fibrillation with clinical symptoms at screening. 3. History of syncope or sustained ventricular tachycardia within 6 months prior to screening. 4. Those who have participated in the clinical trial of any drug or medical device within 3 months before screening. 5. Other conditions that the investigator considers the subject to be unsuitable for participating in this trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-obstructive hypertrophic cardiomyopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuwai Hospital
Beijing, Beijing Municipality, 100032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.